Pliant Therapeutics doses first patient in cancer trial expansion

April 30, 2026 8:30 AM

Pliant Therapeutics (NASDAQ: PLRX) announced it has dosed the first patient in the FORTIFY Phase 1b clinical trial expansion, evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found